Diabetic neuropathy is a neurological disorder associated with diabetes mellitus. The disorder affects all peripheral nerves including autonomic nervous system, pain fibers, and motor neurons. According to World Health Organization (WHO) approximately 350 million people worldwide suffer from diabetes and 80% of them live in low and middle income countries. Furthermore diabetic neuropathy affects 50% of the diabetic patients as per the data.Diabetes thus remains a burning issue in healthcare sector. Though symptoms of the disorder vary according to the nerves affected, common symptoms are abnormal sensations to body parts, erectile dysfunction, loss of control over bladder, dizziness, muscle weakness, intense pain, speech impairment and others.
Total cure for diabetic neuropathy does not exist, but therapeutic treatment can manage the related symptoms. Following therapies can be used for Diabetic neuropathy treatment:
- Transcutaneous Electric Nerve Stimulation (TENS)
The therapies can be directed to the symptoms of the disorder or to control diabetes itself. With the advances in technology, wearable devices have assisted in effectively treating the neuropathy pain. These devices use electric current to block the transmission of pain signals. The treatment is noninvasive, and has minimal side effects as compared to drug treatment.
Diabetes is a growing concern in many countries, especially developing economies which concentrate around 80% of the diabetes population. Currently North America and Europe are the major markets for diabetic neuropathy market owing to the advanced medical services and concentration of market leading companies. Asia Pacific will be most lucrative market in the future with India, Japan and China being main point of focus. There need an increased awareness about the available therapies in the developing economies. Commonly prescribed drugs for diabetic neuropathy are Lyrica, Carbatrol, Neurontin, Pamelor and Cymbalta to a name a few; major players being Pfizer, Glaxo Smith Kline Johnson & Johnson and Eli Lilly. For devices, NeuroMetrix is a significant player through the launch of Sensus which is an FDA approved TENS device for pain management.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
- North America
- Asia Pacific
- Rest of the World
This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Reasons for Buying this Report
• This report provides pin-point analysis for changing competitive dynamics
• It provides a forward looking perspective on different factors driving or restraining market growth
• It provides a technological growth map over time to understand the industry growth rate
• It provides a seven-year forecast assessed on the basis of how the market is predicted to grow
• It helps in understanding the key product segments and their future
• It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
• It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
• It provides distinctive graphics and exemplified SWOT analysis of major market segments
Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.